A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma
Primary Sponsor
Collaborating Groups
TROG Cancer Research
Accrual Target
412
Final Accrual
415
Closing Date of Accrual
20 August 2024
Trial Chairperson
Prof Sandro Porceddu - Princess Alexandra Hospital
Trial Contact
qa@trog.com.au
Related Post
9 January, 2025
Tour de Cure grants support two valuable TROG trials
9 January 2025: Two important TROG Cancer Research trials
7 January, 2025
GenesisCare Foundation $300,000 donation to support TROG work
7 January 2025: TROG Cancer Research is advancing vital
